Please try another search
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis. Abera Bioscience AB was incorporated in 2012 and is based in Uppsala, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Fredrik Juserius | 56 | 2020 | Director |
Camille Locht | - | 2021 | Member of the Advisory Board |
Christina Glad | 71 | 2020 | Director |
Samuel Wagner | - | - | Member of Advisory Board |
Marien de Jonge | - | 2022 | Member of the Advisory board |
Anders Ericsson | 53 | 2015 | Executive Chairman of Board |
Lucille Van Beek | - | 2023 | Member of the Advisory Board |
Florence Vicaire | 52 | 2022 | Director |
Jan-Willem De Gier | - | - | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review